Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Operating Expenses: 2015-2024

Historic Other Operating Expenses for Heron Therapeutics (HRTX) over the last 10 years, with Dec 2024 value amounting to $47.1 million.

  • Heron Therapeutics' Other Operating Expenses rose 17.95% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 0.97%. This contributed to the annual value of $47.1 million for FY2024, which is 30.39% down from last year.
  • Per Heron Therapeutics' latest filing, its Other Operating Expenses stood at $47.1 million for FY2024, which was down 30.39% from $67.6 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Other Operating Expenses ranged from a high of $133.2 million in FY2021 and a low of $47.1 million during FY2024.
  • Moreover, its 3-year median value for Other Operating Expenses was $67.6 million (2023), whereas its average is $65.7 million.
  • Per our database at Business Quant, Heron Therapeutics' Other Operating Expenses skyrocketed by 33.14% in 2021 and then slumped by 38.05% in 2022.
  • Over the past 5 years, Heron Therapeutics' Other Operating Expenses (Yearly) stood at $100.0 million in 2020, then surged by 33.14% to $133.2 million in 2021, then tumbled by 38.05% to $82.5 million in 2022, then fell by 18.02% to $67.6 million in 2023, then slumped by 30.39% to $47.1 million in 2024.